Importantly, CTLA4+ T-cell infiltrate was further enriched in relapsed/refractory cHL patients, suggesting it might protect HRS cells from currently employed therapeutics, including anti-PD-1 antibodies [54]. This evidence concerns the gene CTLA4 and classic Hodgkin lymphoma.